Indocyanine green for sentinel lymph node detection in early breast cancer: Prospective evaluation of detection rate and toxicity-The FLUOBREAST trial.
axillary staging
breast cancer
indocyanine green
sentinel lymph node
Journal
The breast journal
ISSN: 1524-4741
Titre abrégé: Breast J
Pays: United States
ID NLM: 9505539
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
25
05
2020
revised:
05
10
2020
accepted:
05
10
2020
pubmed:
24
10
2020
medline:
22
6
2021
entrez:
23
10
2020
Statut:
ppublish
Résumé
Detection of sentinel lymph node in early breast cancer is commonly based on the combination of patent blue dye and a radioisotope 99m Technetium. Each of these two tracers has advantages and disadvantages leading to the development of the use of indocyanine green. We conducted a prospective clinical trial to compare the detection rate of indocyanine green with 99mTe. Each patient undergoing a sentinel lymph node biopsy for an early breast cancer received both indocyanine green and radioisotopes. The trial was registered: FLUOBREAST EudraCT N 2015-000698-11, ClinicalTrials.gov: NCT02875626. Among a total of 88 patients, 77 were assessable for a total of 205 nodes. Detection rates were 93% for the isotope and 96% for the indocyanine green. The combined detection rate was 99%. The overall concordance rate per patient was 91%. The median number of excised sentinel nodes was 2.3 for each tracer and 2.7 for the combined method (P = .21). All the macrometastatic nodes were detected by both indocyanine green and radioisotopes. The median time between incision of the axilla and removal of the last node was 14 minutes. There was neither allergy nor radio-sensitization linked with the use of indocyanine green. Indocyanine green delivers a high detection rate and sensitivity for the sentinel lymph node biopsy in early breast cancer, with short operative time and a normal number of excised sentinel lymph nodes. Allergy is extremely rare and there is no toxicity. Indocyanine green could be an alternative to radioisotopes to provide an accurate staging of the axilla. Its routine use should be approved.
Substances chimiques
Coloring Agents
0
Indocyanine Green
IX6J1063HV
Banques de données
ClinicalTrials.gov
['NCT02875626']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2357-2363Subventions
Organisme : Fondation de l'Avenir pour la Recherche Médicale Appliquée
ID : AP-MAS-15-001
Organisme : Fondation de l'Avenir
ID : AP-MAS-15-001
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927-933.
Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546-553.
Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599-609.
Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2(6):335-340.
Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391-401.
Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703-7720.
Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7:983-990.
McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560-2566.
Tafra L, Lannin DR, Swanson MS, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg. 2001;233:51-59.
Morrow M, Rademaker AW, Bethke KP, et al. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery. 1999;126(4):714-722.
Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106:4-16.
Salmon RJ, Nos C, Lojodice F, et al. Sentinel node and operable breast cancer: utilization of blue dye injection. Pilot study. Ann Chir. 2000;125:253-258.
Brenet O, Lalourcey L, Queinnec M, et al. Hypersensitivity reactions to Patent Blue V in breast cancer surgery: a prospective multicentre study. Acta Anaesthesiol Scand. 2013;57:106-111.
Derossis AM, Fey J, Yeung H, et al. A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg. 2001;193:473-478.
Bines S, Kopkash K, Ali A, Fogg L, Wool N. The use of radioisotope combined with isosulfan Blue dye is not superior to radioisotope alone for the identification of sentinel lymph nodes in patients with breast cancer. Surgery. 2008;144:606-609.
Kang T, Yi M, Hunt KK, et al. Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann Surg Oncol. 17(Suppl 3):280-285.
Xiong L, Gazyakan E, Yang W, et al. Indocyanine green fluorescence-guided sentinel node biopsy: a meta-analysis on detection rate and diagnostic performance. Eur J Surg Oncol. 2014;40:843-849.
Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. Int J Clin Oncol. 2017;22:11-17.
Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi7-vi23.
Jinno H, Inokuchi M, Ito T, et al. The Japanese Breast Cancer Society clinical practice guideline for surgical treatment of breast cancer, 2015 edition. Breast Cancer. 2016;23:367-377.
Vermersch C, Raia Barjat T, Perrot M, Lima S, Chauleur C. Place of indocyanine green coupled with fluorescence imaging in research of breast cancer sentinel node. Bull Cancer. 2016;103:381-388.
Mazouni C, Koual M, De Leeuw F, et al. Prospective evaluation of the limitations of near-infrared imaging in detecting axillary sentinel lymph nodes in primary breast cancer. Breast J. 2018;24:1006-1009.
Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Measur. 1960;20:37-46.
Andrés AM, Marzo PF. Delta: a new measure of agreement between two raters. Br J Math Stat Psychol. 2004;57:1-19.
Cicchetti DV, Feinstein AR. High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol. 1990;43:551-558.
Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;1:466-469.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-381.
Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-575.
Hillary SL, Guillermet S, Brown NJ, Balasubramanian SP. Use of methylene blue and near-infrared fluorescence in thyroid and parathyroid surgery. Langenbecks Arch Surg. 2018;403:111-118.
Moris V, Cristofari S, Stivala A, et al. Fluorescent indocyanine green angiography: preliminary results in microsurgery monitoring. J Stomatol Oral Maxillofac Surg. 2019;120(4):297-300.
Samorani D, Fogacci T, Panzini I, et al. The use of indocyanine green to detect sentinel nodes in breast cancer: a prospective study. Eur J Surg Oncol. 2015;41:64-70.
Sugie T, Kinoshita T, Masuda N, et al. Evaluation of the clinical utility of the INDOCYANINE GREEN fluorescence method compared with the radioisotope method for sentinel lymph node biopsy in breast cancer. Ann Surg Oncol. 2016;23:44-50.
Mok CW, Tan S-M, Zheng Q, Shi L. Network meta-analysis of novel and conventional sentinel lymph node biopsy techniques in breast cancer. BJS Open. 2019;3:445-452.
Valente SA, Al-Hilli Z, Radford DM, Yanda C, Tu C, Grobmyer SR. Near infrared fluorescent lymph node mapping with indocyanine green in breast cancer patients: a prospective trial. J Am Coll Surg. 2019;228:672-678.
Gueye SMK, Gueye M, Coulbary SA, Diouf A, Moreau JC. Problématique de la prise en charge des cancers du sein au Sénégal: une approche transversale. Pan Afr Med J. 2016;25:3.